0 452

Cited 14 times in

Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors

Authors
 Yong Jun Choi  ;  Taehee Kim  ;  Eun Young Kim  ;  Sang Hoon Lee  ;  Do Sun Kwon  ;  Yoon Soo Chang 
Citation
 THORACIC CANCER, Vol.11(10) : 2793-2803, 2020-10 
Journal Title
THORACIC CANCER
ISSN
 1759-7706 
Issue Date
2020-10
Keywords
Hyperprogressive disease ; NSCLC ; PD-L1 inhibitor ; prognosis
Abstract
Background: Hyperprogressive disease (HPD) is a paradoxical acceleration of tumor growth after immune checkpoint inhibitor (ICI) treatment. This study aimed to identify the risk factors and to present a predictive model for HPD in patients treated with ICIs.

Methods: A total of 78 non-small cell lung cancer (NSCLC) cases, treated with at least two cycles of ICIs who underwent computed tomography (CT) for response assessment were recruited into the study from January 2016 to August 2019. HPD was defined by the following criteria: (i) time-to-treatment failure <2 months; (ii) a 50% increase in the sum of target lesion diameters; (iii) new development of at least two lesions in an already involved organ; (iv) appearance of a new organ lesion; and (v) a decrease in ECOG PS 2.

Results: Of the 78 total patients, 15 (19.2%) had HPD. The risk factors of HPD were age; primary lesion size; and metastases in the contralateral lung, pleura, liver, and bone in multivariable logistic regression (odds ratio [OR]; 0.9038, 1.6619, 28.5913, 23.8264, 14.5711, and 20.1533, respectively, all P-values < 0.05). By using these risk factors, we developed a prediction model for HPD and the area under the receiver operating characteristic curve of the model was 0.9556 (95% confidence interval [CI]: 0.9133-0.9978).

Conclusions: HPD is relatively common and associated with a grave clinical outcome, requiring a careful monitoring in lung cancer patients treated with ICIs. Moreover, risk factors such as age, size of tumor and number of various metastatic lesions should be taken into consideration before ICI administration.

Key points: SIGNIFICANT FINDINGS OF THE STUDY: Age, primary lesion size, and number of metastases are risk factors of HPD. HPD is strongly associated with poor prognosis. HPD during ICI use needs comprehensive monitoring.

What this study adds: This is the first study to develop a prediction model. The area under the curve of the prediction model for HPD was 0.9556.
Full Text
https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.13594
DOI
10.1111/1759-7714.13594
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Do Sun(권도선)
Kim, Eun Young(김은영) ORCID logo https://orcid.org/0000-0002-3281-5744
Lee, Sang Hoon(이상훈) ORCID logo https://orcid.org/0000-0002-7706-5318
Chang, Yoon Soo(장윤수) ORCID logo https://orcid.org/0000-0003-3340-4223
Choi, Yong Jun(최용준) ORCID logo https://orcid.org/0000-0002-6114-2059
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/179932
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links